Zydus Lifesciences share news, announcements and annual reports
NSE: ZYDUSLIFEBSE: 532321Pharmaceuticals & BiotechnologyMid Cap
Zydus Lifesciences Limited · Formerly Cadila Healthcare · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 2000
Last close ₹1,184.40up ₹8.90 (0.76%)BSE ₹1,186.00
Share price at the NSE close on 29 Oct 2026. Previous close ₹1,175.50.
29 Oct: open ₹1,175.50, high ₹1,187.80, low ₹1,170.50
52-week range of traded prices to 29 Oct 2026
₹835.50Low, 2 Apr 2026₹1,232.10High, 29 Sep 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,18,144 Cr114th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 26.18
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹535 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 23.41
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.36
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.08%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 17.7%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹535 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 19.8%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 15.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.40
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 8,55,85055.6% delivered
Zydus Lifesciences shareholder meetings
65 filed, newest first. Page 1 of 2.
Aug 2026
Jul 2026
10 Jul · Meeting
Dec 2025
Nov 2025
11 Nov · Meeting
Aug 2025
Jul 2025
16 Jul · Meeting
Aug 2024
Jul 2024
11 Jul · Meeting
Jul 2023
14 Jul · Meeting
Dec 2022
Aug 2022
Feb 2022
Jan 2022
Aug 2021
Jun 2021
May 2021
Aug 2019
May 2019
Mar 2019
30 Mar · Meeting
Feb 2019
16 Feb · Meeting
Aug 2018
Jul 2018
18 Jul · Meeting
Aug 2017
12 Aug · Meeting
12 Aug · Meeting
12 Aug · Meeting
Jul 2017
18 Jul · Meeting
May 2017
Apr 2017
Aug 2016
Jul 2016
May 2016
Oct 2015
Sep 2015
22 Sep · Meeting
Aug 2015
May 2015
Apr 2015
Aug 2014
8 Aug · Meeting
Jun 2014
2 Jun · Meeting
Register of Members in respect of Equity Shares of the Company shall remain closed from July 21, 2014 to July 30, 2014 (both days inclusive) for the purpose of Annual General Meeting of the Company to be held on July 30, 2014 and payment of dividend for the year ended on March 31, 2014.
Oct 2013
Sep 2013
2 Sep · Meeting
Register of Members in respect of Equity Shares of the Company shall remain closed from September 23, 2013 to September 30, 2013 (both days inclusive) for the purpose of Annual General Meeting of the Company to be held on September 30, 2013.
Aug 2012
May 2012
11 May · Meeting
Register of Members in respect of Equity Shares of the Company shall remain close from July 30, 2012 to August 06, 2012 (both days inclusive) for the purpose of payment of dividend for the year ended March 31, 2012. Further, the Annual General Meeting of the Company will be held on August 06, 2012.